Journal Article

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Yu, Ly-Mee, Detry, Michelle, Hobbs, FD Richard, Saville, Benjamin R, Evans, Philip H, Saunders, Christina, Dorward, Jienchi, Hayward, Gail, Harris, Victoria, Ogburn, Emma, Butler, Christopher C, Berry, Nick, Patel, Mahendra G, de Lusignan, Simon, Van Hecke, Oliver, Thomas, Nicholas PB, Gbinigie, Oghenekome, Fitzgerald, Mark

2021

Overview

Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. We aimed to assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of complications. In this UK-based, primary care, open-label, multi-arm, adaptive platform randomised trial of interventions against COVID-19 in people at increased risk of an adverse clinical course (PRINCIPLE), we randomly assigned people aged 65 years and older, or 50 years and older with at least one comorbidity, who had been unwell for 14 days or less with suspected COVID-19, to usual care plus azithromycin 500 mg daily for three days, usual care plus other interventions, or usual care alone. The trial had two coprimary endpoints measured within 28 days from randomisation: time to first self-reported recovery, analysed using a Bayesian piecewise exponential, and hospital admission or death related to COVID-19, analysed using a Bayesian logistic regression model. Eligible participants with outcome data were included in the primary analysis, and those who received the allocated treatment were included in the safety analysis. The trial is registered with ISRCTN, ISRCTN86534580. The first participant was recruited to PRINCIPLE on April 2, 2020. The azithromycin group enrolled participants between May 22 and Nov 30, 2020, by which time 2265 participants had been randomly assigned, 540 to azithromycin plus usual care, 875 to usual care alone, and 850 to other interventions. 2120 (94%) of 2265 participants provided follow-up data and were included in the Bayesian primary analysis, 500 participants in the azithromycin plus usual care group, 823 in the usual care alone group, and 797 in other intervention groups. 402 (80%) of 500 participants in the azithromycin plus usual care group and 631 (77%) of 823 participants in the usual care alone group reported feeling recovered within 28 days. We found little evidence of a meaningful benefit in the azithromycin plus usual care group in time to first reported recovery versus usual care alone (hazard ratio 1·08, 95% Bayesian credibility interval [BCI] 0·95 to 1·23), equating to an estimated benefit in median time to first recovery of 0·94 days (95% BCI −0·56 to 2·43). The probability that there was a clinically meaningful benefit of at least 1·5 days in time to recovery was 0·23. 16 (3%) of 500 participants in the azithromycin plus usual care group and 28 (3%) of 823 participants in the usual care alone group were hospitalised (absolute benefit in percentage 0·3%, 95% BCI −1·7 to 2·2). There were no deaths in either study group. Safety outcomes were similar in both groups. Two (1%) of 455 participants in the azothromycin plus usual care group and four (1%) of 668 participants in the usual care alone group reported admission to hospital during the trial, not related to COVID-19. Our findings do not justify the routine use of azithromycin for reducing time to recovery or risk of hospitalisation for people with suspected COVID-19 in the community. These findings have important antibiotic stewardship implications during this pandemic, as inappropriate use of antibiotics leads to increased antimicrobial resistance, and there is evidence that azithromycin use increased during the pandemic in the UK. UK Research and Innovation and UK Department of Health and Social Care.

• Publisher: Elsevier Ltd,Elsevier B.V,Elsevier Limited,Elsevier
• Subject: Age Factors / Aged / Aged, 80 and over / Anti-inflammatory agents / Antibiotics / Antimicrobial resistance / Antimicrobial Stewardship / Antiviral activity / Antiviral agents / Antiviral drugs / Azithromycin / Azithromycin - pharmacology / Azithromycin - therapeutic use / Bacterial infections / Bayesian analysis / Clinical trials / Coronaviruses / COVID-19 / COVID-19 - complications / COVID-19 - diagnosis / COVID-19 - immunology / COVID-19 Drug Treatment / Cytokine Release Syndrome - immunology / Cytokine Release Syndrome - prevention & control / Cytokine Release Syndrome - virology / Drug Resistance, Bacterial / Ethics / Female / Health care / Hospitals / Humans / Infections / Inflammation / Intervention / Male / Middle Aged / Older people / Pandemics / Patient Admission - statistics & numerical data / Primary care / Randomization / Recovery / Regression analysis / Regression models / Risk / Risk Factors / Safety / SARS-CoV-2 - drug effects / SARS-CoV-2 - isolation & purification / Severe acute respiratory syndrome coronavirus 2 / Statistical analysis / Time Factors / Treatment Outcome / United Kingdom